As MTX was shown to not be sufficiently effective in decreasing arthritis-stimulated IL-1β gene expression [64], the use of drugs such as CA capable of increasing the anti-inflammatory action of MTX could represent a promising supplement therapy. Here, IL1B is linked to arthritic joint disease.